Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose

• Status: Not yet recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives of this study are:

1. To obtain information on the pharmacokinetics of cytisinicline following a single oral dose in subjects with varying degrees of renal impairment relative to matched controls with normal renal function.

2. To investigate the extent of cytisinicline removal by hemodialysis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Achieve Life Sciences

Criteria

Inclusion Criteria:

• Free written informed consent prior to any procedure required by the study.

• Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.

• Willingness to accept and comply with all study procedures and restrictions.

• Male or female subject between 18 and 75 years, inclusive, at Screening.

• Body mass index (BMI) of 18.0 to 35.0 kg/m^2, inclusive, at Screening.

• A female subject is eligible if she meets one of the following criteria:

1. is of non-childbearing potential (underwent a permanent sterilization method [e.g., hysterectomy, bilateral salpingectomy and bilateral oophorectomy], is clinically diagnosed infertile, or is in a post-menopausal state); or

2. is of childbearing potential and agrees to use an accepted contraceptive method from at least 28 days prior to dose administration (prior to first dose administration for Group 5) until at least 1 month after the end of study (EOS).

• Negative test results for anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (anti-HCVAb).

• Stable concomitant medications for at least 7 days prior to dose administration (first dose administration for Group 5) and up to the EOS.

Additional Inclusion Criteria for Subjects with Renal Impairment (Groups 2 to 5)

• eGFR at Screening, determined by the Cockcroft-Gault equation, within:

• 60-89 mL/min for Group 2 (mild renal impairment subjects).

• 30-59 mL/min for Group 3 (moderate renal impairment subjects).

• 15-29 mL/min for Group 4 (severe renal impairment subjects).

• <15 mL/min for Group 5 (ESRD subjects)

• Subjects with ESRD are on dialysis for at least 3 months prior to Screening.

• Systolic blood pressure (SBP) 100-180mmHg, diastolic blood pressure (DBP) 50-105 mmHg, and pulse rate 50-100 bpm (inclusive), at Screening and Admission.

Additional Inclusion Criteria for Subjects with Normal Renal Function (Group 1)

• Estimated glomerular filtration rate (eGFR) ≥90 mL/min at Screening, determined by the Cockcroft-Gault equation.

• No clinically relevant abnormalities on clinical laboratory tests at Screening.

• Blood pressure and pulse rate at Screening within the following ranges:

• SBP 90-140 mmHg, DBP 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects <65 years of age.

• SBP 95-160mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥65 years of age.

Exclusion Criteria:

• Known hypersensitivity/allergy reaction to cytisinicline substance or any of the excipients.

• History of renal, heart, and/or liver transplant.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment except for renal disease.

• Symptoms of an acute clinically relevant infection in the 4-week period preceding Screening (e.g., bacterial, viral, or fungal infection).

• History or clinical evidence of alcohol use disorder or substance use disorder according to Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) classification, within the 3-year period prior to Screening.

• Clinically relevant abnormalities on a 12-lead electrocardiogram (ECG), recorded after 5 min in the supine position at Screening.

• Currently using any creatine supplement.

• Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 hours prior to Admission.

• Excessive caffeine consumption, defined as ≥800 mg per day at Screening.

• Positive result in drugs-of-abuse or ethanol tests at Screening or Admission. NOTE:

Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.

• Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).

• Participation in any clinical trial within the previous 2 months.

• Loss of 250 mL or more blood within 3 months prior to screening.

• If female, positive pregnancy test in serum at Screening or positive pregnancy test in urine at Admission.

• If female, she is breast-feeding.

Additional Exclusion Criteria for subjects with Renal Impairment (Group 2 to 5)

• Presence of severe cardiac disease.

• History of severe renal artery stenosis.

• Presence of unstable diabetes mellitus.

• Acute, ongoing, recurrent, or chronic systemic disease other than renal function impairment that could interfere with the evaluation of the study results.

• Presence of any organ disorder, except for renal function impairment, which might interfere with the PK of cytisinicline.

• Use of any medication which might interfere with the PK of cytisinicline.

• Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis), except for those related to renal impairment, at Screening.

Additional Exclusion Criteria for Subjects with ESRD (Group 5)

• Blood hemoglobin <10 g/dL at Screening.